Valero Energy Partners LP(VLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VLP Valero Energy Partners LP

Delisted 12-09 16:00:00 EST

42.24

+0.00

0.00%

High42.24	Low42.24	Vol0.00
Open42.24	D1 Closing42.24	Amplitude0.00%
Mkt Cap2.93B	Tradable Cap702.45M	Total Shares69.26M
T/O0.00	T/O Rate0.00%	Tradable Shares16.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VLP","market":"US","secType":"STK","nameCN":"Valero Energy Partners LP","latestPrice":42.24,"timestamp":1575925200000,"preClose":42.24,"halted":4,"volume":0,"delay":0,"floatShares":16630000,"shares":69262070,"eps":2.843937,"marketStatus":"Delisted","change":0,"latestTime":"12-09 16:00:00 EST","open":42.24,"high":42.24,"low":42.24,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.843937,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1725868800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1386738000000,"exchange":"NYSE","adjPreClose":42.24,"volumeRatio":0},"requestUrl":"/m/hq/s/VLP","defaultTab":"news","newsList":[{"id":"2462123069","title":"Rackspace Introduces On-demand Software as a Service to Seamlessly Simulate Complex Environments","url":"https://stock-news.laohu8.com/highlight/detail?id=2462123069","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462123069?lang=en_us&edition=fundamental","pubTime":"2024-08-26 23:05","pubTimestamp":1724684700,"startTime":"0","endTime":"0","summary":"Rackspace Lab Services merges Broadcom VMware Lab Platform and Rackspace SDDC Flex for a cutting-edge cloud solution to transform organizations worldwideSAN ANTONIO, Aug.  26, 2024  (GLOBE NEWSWIRE) -","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/26/2935660/0/en/Rackspace-Introduces-On-demand-Software-as-a-Service-to-Seamlessly-Simulate-Complex-Environments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXT","VLP","BK4116"],"gpt_icon":0},{"id":"2458727703","title":"Press Release: HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2458727703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458727703?lang=en_us&edition=fundamental","pubTime":"2024-08-09 07:20","pubTimestamp":1723159200,"startTime":"0","endTime":"0","summary":"$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024. The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults. BOSTON, Aug. 08, 2024  -- HilleVax, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2024 and highlighted recent progress.-- In Q3 2024, HilleVax announced that the NEST-IN1 clinical study did not. meet its primary or secondary efficacy endpoints and that the company. would discontinue further development of HIL-214 in infants.of its workforce to reduce operating expenses while maintaining core. capabilities as the company explores the potential for continued. development of its HIL-214 and HIL-216 norovirus candidates as well as. Research and development expenses for the second quarter 2024 were $26.6 million, compared to $23.0 for the second quart","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HLVX","BK4139","PRGS","LU2065732104.USD","VLP","BK4097"],"gpt_icon":0},{"id":"2456167530","title":"HilleVax Announces Reduction in Force","url":"https://stock-news.laohu8.com/highlight/detail?id=2456167530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456167530?lang=en_us&edition=fundamental","pubTime":"2024-08-01 04:00","pubTimestamp":1722456000,"startTime":"0","endTime":"0","summary":"BOSTON, July  31, 2024  (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workfo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/31/2922200/0/en/HilleVax-Announces-Reduction-in-Force.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VLP"],"gpt_icon":0},{"id":"2449776472","title":"HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants","url":"https://stock-news.laohu8.com/highlight/detail?id=2449776472","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449776472?lang=en_us&edition=fundamental","pubTime":"2024-07-08 19:30","pubTimestamp":1720438200,"startTime":"0","endTime":"0","summary":"The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/08/2909536/0/en/HilleVax-Reports-Topline-Data-from-NEST-IN1-Phase-2b-Clinical-Study-of-HIL-214-in-Infants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VLP","HIL","BK4123"],"gpt_icon":0},{"id":"2434665047","title":"HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2434665047","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2434665047?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:05","pubTimestamp":1715285100,"startTime":"0","endTime":"0","summary":"Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024. $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024. BOSTON, May 09, 2024  -- HilleVax, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle  based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its most advanced program, HIL-214, is a virus-like particle  based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis  caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0cPV1gz.UkD5iL1gxGQ2Og--~B/aD0xODc7dz05MDk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d2fb5a18e2eaedd3d42d48d3491eecaf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0cPV1gz.UkD5iL1gxGQ2Og--~B/aD0xODc7dz05MDk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d2fb5a18e2eaedd3d42d48d3491eecaf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hillevax-reports-first-quarter-2024-200500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","HLVX","PRGS","BK4097","LU2065732104.USD","VLP"],"gpt_icon":0},{"id":"2427826553","title":"VBI Vaccines Reports Full Year 2023 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2427826553","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2427826553?lang=en_us&edition=fundamental","pubTime":"2024-04-16 20:00","pubTimestamp":1713268800,"startTime":"0","endTime":"0","summary":"PreHevbrio  global net revenue increased 234% year-over-year from 2022 to 2023. Preliminary 2024 PreHevbrio U.S. sales demonstrate continued growth, with approximately 65% of 2023 full-year volume sold in Q1 2024 alone. Early data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma  demonstrate encouraging separation of tumor response trends between VBI-1901 study arm and standard-of-care arm. Additional interim data readouts from randomized, controlled Phase 2b study of VBI-1901 in recurrent GBM expected mid-year and year-end 2024. CAMBRIDGE, Mass., April 16, 2024----VBI Vaccines Inc.  , a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/p6wSkAKo_iEyUI1.tzy3mg--~B/aD0zODc7dz05NDE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/37f7cfbc974c34a5c89017460f5249e9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/p6wSkAKo_iEyUI1.tzy3mg--~B/aD0zODc7dz05NDE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/37f7cfbc974c34a5c89017460f5249e9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vbi-vaccines-reports-full-2023-120000469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","SD","VLP","BK4139","VBIV"],"gpt_icon":0},{"id":"2421703958","title":"Press Release: HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2421703958","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2421703958?lang=en_us&edition=fundamental","pubTime":"2024-03-21 04:00","pubTimestamp":1710964800,"startTime":"0","endTime":"0","summary":"Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024. Enrollment for NEST-IN1 study completed in Q2 2023. $303.5 million of cash, cash equivalents and marketable securities as of December 31, 2023. BOSTON, March 20, 2024  -- HilleVax, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle  based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.\"Over the past year, we made significant progress with HIL-214, our vaccine candidate for the prevention of moderate-to-severe norovirus related acute gastroenteritis. We have continued to progress the NEST-IN1 clinical trial and remain on track to report topline data by mid-2024,\" said Rob Hershberg, MD, PhD, Chairman ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","HLVX","VLP","SEC.AU","BK4139","BK7083","AGE","PRGS","LU2065732104.USD","AGE.AU"],"gpt_icon":0},{"id":"2419952094","title":"Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9","url":"https://stock-news.laohu8.com/highlight/detail?id=2419952094","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2419952094?lang=en_us&edition=fundamental","pubTime":"2024-03-13 15:00","pubTimestamp":1710313200,"startTime":"0","endTime":"0","summary":"Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers. Merck , known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types. Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL9 , compared to the approved three-dose regimen.Merck vaccine researchers continue to build on the development of GARDASIL and GARDASIL 9 to identify new candidates with the potential to extend protection against a broader array of HPV types. The latest addition to the pipeline employs the company’s proprietary virus-like particle  technology to incorporate additional VLPs for expanded HPV type coverage. This includes several types known to have more impact ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22922779","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["LU2106854487.HKD","IE00BLSP4239.USD","LU0320765489.SGD","SG9999014575.USD","IE00B1BXHZ80.USD","LU1066053197.SGD","LU0861579265.USD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","BK4516","AIN","IE00BLSP4452.SGD","LU1585245621.USD","LU1023059063.AUD","BK4588","LU0234572021.USD","SG9999014559.SGD","LU2461242641.AUD","LU0266013472.USD","SG9999013999.USD","SG9999002224.SGD","BK4550","IE0009355771.USD","LU1430594728.SGD","BK4585","LU1057294990.SGD","LU1917777945.USD","SG9999001440.SGD","LU0238689110.USD","LU2468319806.SGD","MRK","LU2023250843.SGD","LU0965509283.SGD","SG9999014567.USD","IE0002141913.USD","SG9999002232.USD","LU1291159041.SGD","SG9999015358.SGD","SG9999014542.SGD","VLP","LU0070302665.USD","LU0965509101.SGD","IE00B2B36J28.USD","LU1974910355.USD","LU0965509010.AUD","IE00BSNM7G36.USD","LU0208291251.USD","BK4161","BK4559","LU2023250504.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.valeroenergypartners.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0414},{"period":"1month","weight":0.0418},{"period":"3month","weight":0.0119},{"period":"6month","weight":0.056},{"period":"1year","weight":0.2147},{"period":"ytd","weight":0.1369}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Valero Energy Partners LP owns, operates, develops, and acquires crude oil and refined petroleum products pipelines, terminals, and other transportation and logistics assets in the United States. Its assets include crude oil and refined petroleum products pipeline and terminal systems, including Port Arthur logistics system, McKee products system, Memphis logistics system, Three Rivers Crude System, Wynnewood Products System, Houston Terminal, St. Charles Terminal, and Corpus Christi Terminals located in the Gulf Coast and Mid-Continent regions of the United States. Valero Energy Partners GP LLC serves as the general partner of the company. Valero Energy Partners LP was founded in 2013 and is headquartered in San Antonio, Texas.","exchange":"NYSE","name":"Valero Energy Partners LP","nameEN":"Valero Energy Partners LP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.3","shortVersion":"4.26.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Valero Energy Partners LP(VLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Valero Energy Partners LP(VLP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Valero Energy Partners LP,VLP,Valero Energy Partners LP股票,Valero Energy Partners LP股票老虎,Valero Energy Partners LP股票老虎国际,Valero Energy Partners LP行情,Valero Energy Partners LP股票行情,Valero Energy Partners LP股价,Valero Energy Partners LP股市,Valero Energy Partners LP股票价格,Valero Energy Partners LP股票交易,Valero Energy Partners LP股票购买,Valero Energy Partners LP股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Valero Energy Partners LP(VLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Valero Energy Partners LP(VLP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction